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INTRODUCTION 
Chronic kidney disease (CKD) is emerging as a global pandemic 
but it is a highly under recognized health problem in India .CKD ranks the 
3rd amongst the leading life-threatening disease following cancer and 
cardiac ailments.16 
March 9 is observed as World kidney day by the WHO to create 
awareness among the people about the magnitude of this deadly disease 
and start early treatment to reduce the mortality and morbidity from this 
disease. 
Every 10th person is suffering from CKD and by this calculation we 
are having 100 millions people suffering from CKD in India. 
  
Statistics have revealed a doubling of incidence in past few years39 
(US NHANES III 1988 to 94 - 3%). 
Since CKD is often asymptomatic until End stage renal disease 
(ESRD) sets in, this estimation may only be akin to the tip of an iceberg  
Increasing patient burden causes a considerable proportion of 
available healthcare resources to be spent on renal replacement therapy 
(RRT). 
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The enormous cost for dialysis and transplantation procedures post 
transplant medicines and the relative lack of technical centers providing 
these facilities is a big challenge before us. 
Hence CKD has been globally recognized as a major economic and 
organizational concern. 
CKD has been aptly mentioned as the “The Silent Killer”. In a 
developing country like ours we can ill afford the treatment of end stage 
renal disease and hence it is important for us to understand prevent and if 
not manage CKD well. 
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AIMS AND OBJECTIVES 
 
 
 
1. To assess the nutritional status of patients with chronic kidney 
disease in and around Madurai. 
2. To detect the incidence and nature of anemia in patients with 
chronic kidney disease. 
3. To find out the prevalence of iron deficient state in patients with 
chronic kidney disease in comparison with normal controls. 
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REVIEW OF LITERATURE 
 
 Chronic kidney disease has become a global epidemic. 
Management of such a devastating disease is a highly complicated issue 
even among the well developed countries.  
 
Medical, ethical, psychological and socio-economic problems 
associated with CKD is a large burden to the healthcare sector of the 
developing countries like India. 
Definition of CKD: National Kidney Foundation(NKF) has 
defined CKD16 
Criteria : 
1. .Kidney damage > 3months ,either structural or functional  
abnormality with or without decreased glomerular filtration rate (GFR) 
,manifested by either pathologic abnormalities or markers of kidney 
damage in blood, urine or imaging studies. 
2.GFR < 60 ml/min /1.73 m2  > 3 months with or without kidney 
damage 
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Though  many etiologies predispose to CKD the clinical 
consequences of renal failure are the same and ultimately contribute to the 
morbidity and mortality of the disease.  The major consequence of CKD 
is premature death due to cardio vascular disease (CVD).17,18 Recently 
revealing data have highlighted that even small increases in serum 
creatinine levels have a huge impact on cardiovascular mortality19,20.  
Causes of chronic renal failure: 
Primary glomerulonephritis: 
¾ Proliferative 
¾ Focal glomerulosclerosis 
¾ Membranous 
¾ Membranoproliferative 
¾ Crescentic 
Secondary :  
¾ Diabetes mellitus (DM) 
¾ Systemic lupus erythematosus (SLE)  
¾ Amyloidosis  
¾ Vasculitis 
Interstitial disease:  
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¾ Chronic interstitial disease   
¾ Chronic pyelonephritis  
¾ Reflux nephropathy 
Hypertensive renal disease: 
¾ Nephrosclerosis 
¾ Renal artery stenosis 
Obstructive uropathy: 
¾ Urinary calculus disease  
¾ Prostatic enlargement    
¾ Tumors  
Heredofamilial renal disease:  
¾ Autosomal polycystic kidney disease (ADPKD)  
¾ Medullary cystic renal disease  
¾ Alports syndrome  
Comparing the causes of ESRD allover the globe there is a striking 
difference between the western and Indian population. In the USA the 
leading cause of ESRD is diabetes mellitus , next being hypertension but 
in our country even though large scale data are not available the leading 
cause of ESRD is glomerulonephritis over diabetes and hypertension. 
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Other causes like interstitial nephritis, HIV nephropathy etc also forms a 
significant proportion of cases leading to ESRD.  
 
STAGES OF CHRONIC KIDNEY DISEASE 
Stage Description GFR 
(mL/min/1.73m2)
Action 
 
1 Kidney damage with 
normal GFR 
> 90 Diagnosis and treatment of comorbid 
condition, Slow progression, CVD risk 
reduction  
2 Kidney damage with 
mild reduction of GFR 
60 – 89 Estimating progression 
 
3 Moderate reduction of 
GFR 
30 – 59 Evaluate and treat complications 
4 Severe reduction of 
GFR 
15 – 29 Preparation for kidney replacement 
therapy  
5 Kidney failure < 15 or dialysis Renal replacement therapy 
 
Thus there is a need for early detection and treatment. 
The significance of National kidney foundation – kidney disease outcome 
quality initiative ( NKF-K/DOQI) staging : 
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• Shift of  focus –GFR as the sole criteria for defining chronic renal 
disease to the identification of harbingers  of early kidney damage 
including proteinuria, and abnormal urine sediment  
• The concept of CKD with normal GFR but markers of  kidney 
damage like persistent proteinuria is rewarding as an optimal 
treatment at this early stage may arrest the progression of illness. 
• Hence they should form the main focus of preventive strategies. 
This staging helps to plan further treatment and predict outcome.  
Malnutrition is an important consequence of CKD due to 
various reasons esp. the people on dialysis and caries a poor 
prognosis. 
 
Protein-energy malnutrition (PEM) is very common among patients 
with advanced chronic renal failure (CRF) and those undergoing 
maintenance dialysis (MD) therapy worldwide. Different reports suggest 
that the prevalence of this condition varies from roughly 18% to 70% of 
adult MD patients. In adults, the presence of PEM is one of the strongest 
predictors of morbidity and mortality. However, in the poorly nourished 
pediatric patient, mortality is less common, and growth retardation is an 
 9
additional and greater concern. Impaired linear growth persists despite 
ongoing renal replacement therapy with either hemodialysis (HD) or 
peritoneal dialysis, and improvements in linear growth after successful 
renal transplantation usually fail to fully correct pre-existing growth 
retardation unless growth hormone (GH) is administered. Although 
several factors contribute to the impaired skeletal growth in pediatric 
patients with chronic renal disease, protein and energy malnutrition play a 
critical role, particularly during the first few years of life. Additional 
factors that contribute to impaired growth in pediatric patients include 
anemia, acidemia, calcitriol deficiency, renal osteodystrophy, and tissue 
resistance to the actions of GH and insulin-like growth factor-I (IGF-I 
There are many causes of PEM in patients with advanced CRF.1,4,7 
These include:  
(a) Inadequate food intake secondary to:  
¾ Anorexia caused by the uremic state  
¾ Altered taste sensation  
¾ Intercurrent illness  
¾ Emotional distress or illness  
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¾ Impaired ability to procure, prepare, or mechanically ingest foods  
¾ Unpalatable prescribed diets  
(b) The catabolic response to superimposed illnesses 
(c) The dialysis procedure itself, which may promote wasting by 
removing such nutrients as amino acids, peptides, protein, glucose, water-
soluble vitamins, and other bioactive compounds, and may promote 
protein catabolism, due to bioincompatibility 
(d) Conditions associated with chronic renal failure that may induce a 
chronic inflammatory state and may promote hypercatabolism and 
anorexia 
(e) Loss of blood due to:  
¾ Gastrointestinal bleeding  
¾ Frequent blood sampling  
¾ Blood sequestrated in the hemodialyzer and tubing  
(f) Endocrine disorders of uremia (resistance to the actions of insulin and 
IGF-1, hyperglucagonemia, and hyperparathyroidism) 
(g) Possibly the accumulation of endogenously formed uremic toxins or 
the ingestion of exogenous toxins. 
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Serum Albumin44,45,46 
      The concentration of serum albumin has long been used as an index 
of protein nutrition, even though it responds relatively slowly to changes 
in protein stores because of a half-life of about 20 days. Hence, plasma 
albumin levels in malnourished patients are only slowly restored to 
normal during protein refeeding.43 When hypoalbuminemia occurs in non-
nephrotic CRF patients, it should be viewed as a sign of protein 
malnutrition. 
There are, however, other factors that influence the albumin 
concentration. Kaysen and co-workers have emphasized that albumin 
synthesis falls sharply in subjects with inflammatory illnesses (i.e., 
albumin functions as a ‘negative’ acute phase reactant).46,44,45 In studying 
the causes of hypoalbuminemia in dialysis patients, they found that there 
is a relationship between hypoalbuminemia and an inadequate diet, but 
they also noted that there is a relationship with higher serum levels of 
amyloid A and C-reactive protein, the acute-phase reactant proteins. 
Qureshi and associates found a relationship between hypoalbuminemia 
and higher levels of C-reactive protein, and noted that C-reactive protein 
levels were associated with malnutrition in their cross-sectional study of 
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hemodialysis patients.61 It is not settled whether these relationships are 
nonspecific or whether they are related to inflammation associated with 
the dialysis treatment. Regarding the influence of nutritional factors, there 
is evidence that the serum albumin concentration is stable or even rises in 
patients with progressive renal insufficiency when they are receiving 
proper dietary instructions.62,63-65 
Anthropometrics 
     Evaluation of abnormal anthropometry in CRF patients is complicated, 
because most reports are based on a single evaluation and the 
measurements are compared to those of normal healthy adults.47 
Moreover, the interpretation of abnormal values is questionable. For 
example, there are reports of normal values of serum proteins, even 
though anthropometric changes were compatible with loss of muscle 
mass.48,49 Kopple66 and Bergstrom50 conclude that there is a high 
incidence of anthropometric abnormalities in virtually all cross-sectional 
studies of dialysis patients, suggesting malnutrition. This conclusion, plus 
the observation that the average protein intake of predialysis patients 
decreases with advancing renal insufficiency,67 have led some to suggest 
that dialysis should be initiated early to avoid malnutrition and improve 
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the prognosis.51,52 However, it is unlikely that anthropometric 
abnormalities can be generally attributed to low-protein diets prescribed 
during the predialysis period.65 When predialysis patients were examined 
before and after 1 year of amino acid- and ketoacid-supplemented 
regimens, no decrease in nutritional status was seen, as indicated by 
changes in plasma proteins or anthropometry.53,54 Similarly, long-term (6 
to 72 months) observation of patients treated with the same supplements 
revealed normal values of serum albumin and transferrin.63 The 
importance of anthropometrics in assessing the effectiveness of nutritional 
therapy is limited, especially if data are only from a single measurement 
in a cross-sectional analysis of nutritional status. 
 
 
THE ANEMIA OF CHRONIC RENAL FAILURE  
The anemia is a well known and major complication of CKD and is 
considered a hall mark of chronicity of renal disease.1 It is multifactorial 
in origin even though traditionally considered as normocytic 
normochromic anemia due to erythropoetin deficiency other factors like 
iron deficiency contribute a major proportion and this is worsened in 
patients on dialysis and erythropoietin therapy  
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1. Decreased Erythropoietin production  
a) Plasma erythropoietin  (EPO) levels are inappropriately low for the 
degree of anaemia. The normal feedback mechanism operate poorly 
in increasing erythropoietin secretion.1,3,7  
b) Oxygen dependency is still maintained but operates at a much 
lower level of sensitivity.7 
c) Neocytolysis is a pathological process affecting selectively the 
young RBC’s. EPO depression appear to initiate this process. 
Though the exact mechanism is unknown, it is postulated that 
endothelial cells secrete cytokines influencing adhesive interactions 
between young RBC’s and reticulo endothelial phagocytes.28 
2. Decreased Erythrocyte survival  
a) Metabolic factors  
i) Reduced HMP shunt activity renders cells sensitive to 
oxidative stresses. 
ii) Hyperparathyroidism contribute to haemolysis by 
increasing red cell osmotic fragility. 
iii) Use of immunohemolytic drugs like alphamethyldopa 
adds to the problems.1,3,6 
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b) Mechanical factors  
Microangiopathic hemolytic anemia resulting from 
hypertension.6,10  
c) Hypersplenism  
Splenomegaly may occur secondary to marrow fibrosis, 
chronic hepatitis and transfusion hemosiderosis.6 
3. Blood Loss  
a. Chronic gastrointestinal and genitourinary loss  
b. Dialyser loss 
c. Loss from fistulae 
d. Blood loss from repeated bleeding for investigations. 
 
4. Platelet dysfunction  
a) Defective function of Glycoprotiein Gp II b – III a 
complex.21,20 
b) Functional defect in von willebrand factor VWF – platelet 
interaction  
c) Increased prosta glandin (PGI2) secondary to 
hyperparathyroidism 
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d) Decreased granule content of Adenosine di phosphate  
(ADP). 
e) Increased oxygen derived free radicals. 
f) Reduced life - span of platelets due to reduced 
thrombopoietin. 
5. Uremic inhibitors of erythropoiesis  
 The various uremic toxins postulated are 7,23,24 
 a) Byproducts of protein and aminoacid metabolism  
I. Urea – 80% of total excreted nitrogen. 
II. Guanidine Compounds (Guanidine, methyl guanidine, 
Creatinine, Creatine etc). 
III. Urates and hippurates. 
IV. End products of aliphatic amine metabolism 
V. End products of aromatic aminoacid metabolism 
(tryptophan, tyrosine, phenylalanine) 
VI. Other nitrogenous substances (myoinositol, polyamines, 
phenols etc). 
b. Advanced glycation end  products  
c. Inhibitors of ligand – protein binding  
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d. Glucurono conjugates and aglycones 
e. Inhibitors of somatomedin and insulin action. 
 
6. Aluminium toxicity  
 It occurs in patients on chronic haemodialysis patients and also 
with chronic use of aluminium hydroxide as phosphate binder. 
Aluminium inhibits erythropoiesis by interfering with iron transport and 
or its utilisation, inhibition of heme synthesis or increased hemolysis due 
to increased red cell fragility.7,25,26 
 
 
7. Nutritional factors  
 Anorexia from uremia and various drugs and dietary restriction lead 
to iron deficiency and folate deficiency.1,7 
 
8. Inflammation 
 The inflammatory mediators that are known to be in increased 
levels like cytokines Tumour necrosis factor-alpha and interferon gamma 
are also known to inhibit erythropoiesis.78,79 
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CORRECTABLE CAUSES OF ANAEMIA IN CRF6  
 
Causes     Mechanism  
1.Blood loss    a. Iatrogenic loss  
     b. Dialyser loss  
     c. Loss through fistula or shunt 
     d. GI loss 
 
2. Folate deficiency  a. Increased demand  
     b. Restricted intake  
     c. Dialyser loss  
     d. Drugs  
 
3. Acclerated Haemolysis       
 i) Dialyser associated  a. Chemicals (copper,  
    chloramines, formaldehyde,    
    nitrates). 
b. Overheating of RBC’s. 
c. Mechanical fragmentation  
     of RBC’s  
d. Dehydration or  
    overhydration of RBC’s 
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  ii) Drugs    a. Oxidant drugs  
      b. Immunohemolytic drugs like 
          Alphamethyldopa. 
  iii) Microangiopathy a. Hypertension  
      b. Vasculitis  
  iv) Red cell phosphate  a. Excessive intake of antacids  
   leading to deplet on. 
 
PARAMETERS USED TO STUDY IRON STORES  
1. Serum iron (SI) 
2. Total iron binding capacity (TIBC) 
3. Percentage saturation of transferrin (%) TSAT 
4. Serum ferritin (SF) 
5. Marrow sideroblasts. 
6. Red cell protoporphyrin  
7. Serum transferrin receptor (TfRC) 
1. Serum iron  
The serum iron level represents the amount of circulating iron 
bound to transferrin. 
    Normal range is 50-150 micrograms/dl.     
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2. TIBC 
It is an indirect measure of circulating transferrin. The normal range 
is 300-360 micrograms/dl. 
3. Percentage saturation of transferrin. (TSAT) 
It is calculated using  the formula  
 Serum Iron x 100  
      TIBC  
Normal transferrin saturation is 25-50%. Iron deficiency is 
associated with a saturation of <16%. A transferrin saturation of >50% 
indicates that a disproportionate amount of iron bound to transferrin is 
being delivered to non erythroid tissues. 
4. Serum ferritin1 
Serum ferritin exists in equilibrium with  tissue stores of iron . The 
normal value of ferritin varies according to the gender. 
Adult males have an average of 100 microgram/dl. Adult females 
have levels averaging 30 microgram/dl.  
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5. Estimation of bone marrow stores 
This is the most accurate method of detecting iron stores.6 
However because it is invasive it has been replaced by the estimation 
of serum ferritin. The iron store measurements.  
 
Iron Stores Marrow iron stain  
(0-4+) 
Serum Ferritin  
(Miccrogm/l) 
0 
1-300mg 
300-800mg 
800-1000mg 
1-2gms 
iron overload  
0 
Traces to 1+ 
2+ 
3+ 
4+ 
- 
<15 
15-30 
30-60 
60-150 
> 150 
> 500-1000 
 
Marrow sideroblasts which normally constitute 40-60% have 
visible ferritin granules. In iron deficiency its value falls. 
 
6. Red cell protoporphyrin levels  
It is an intermediate in the pathyway of heme synthesis. Under 
conditions in which heme synthesis is impaired, protoporphyrin 
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accumulates within the red cell. This reflects an inadequate iron supply to 
erythroid precursors to support hemoglobin synthesis.  
Normal values is less than 30 microgram/dl. 
RBC INDICES 
 The red cell indices are calculated mean values that reflect the size, 
weight and haemoglobin (Hb) content of individual erythrocytes. They 
consist of  
• Mean corpuscular volume (MCV) 
• Mean corpuscular haemoglobin (MCH) 
• Mean corpuscular haemoglobin concentration (MCHC). 
MCV – indicates volume of Hb in each cell. 
MCH – indicates weight of Hb in each cell 
MCHC – indicates the proportion of haemoglobin contained in each 
red cell. 
 Using the red cell indices anaemias are classified as  
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ANAEMIA MCV (fl) MCH (pg) MCHC (%)
Normal  
Hypochromic microcytic  
Normochromic microcytic 
Normochromic macrocytic  
Normochromic normocytic  
90±9 
50-80 
<80 
95-150 
82-92 
32±2 
12-25 
20-25 
30-50 
25-30 
33±3 
25-30 
<27 
32-36 
32-36 
 
STAGES OF IRON DEFICIENCY ANAEMIA  
 Iron deficiency anaemia is the condition in which there is anaemia 
and clear evidence of iron deficiency. However it is worthwhile to 
consider the steps by which iron deficiency anaemia occurs. It can be 
divided into three stages.3,9 
a. Stage of prelatent iron deficiency or iron depletion2,3  
 This represents a reduction in iron stores without reduced serum 
iron levels. This stage is usually detected by a low serum ferritin level. 
Latent iron deficiency is said to exist when iron stores are exhausted, but 
the blood hemoglobin level remains higher than the lower limit of normal.   
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b. Stage of iron deficient erythropoiesis 
 In this second stage, certain biochemical abnormalities of iron – 
limited erythropoiesis may be detected, including reduced transferrin 
saturation, increased TIBC, increased free erythrocyte protoporphyrin, 
increased zinc protoporphyrin, and increased serum TfRC. Other findings 
include subnormal urinary iron excretion after deferoxamine injection and 
decreased tissue cytochrome oxidase levels. The mean corpuscular 
volume usually remains within normal limits, but a few microcytes may 
be detected on a blood smear. Many patients report generalized fatigue or 
malaise, even though they are not yet anemic.  
c. Stage of iron deficient anaemia 
 In this stage the blood hemoglobin concentration falls below the 
lower limit of normal, and iron deficiency anemia is apparent. Iron-
containing enzymes, such as the cytochromes, also reach abnormally low 
levels during this period. This stage is characterized by hypochromic, 
microcytic cells, TIBC increases, percentage saturation is much less and a 
very low levels of serum ferritin.  
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Stages in the Development of Iron Deficiency2  
 Stage 1  
(Prelatent) 
Stage 2  
(Latent) 
Stage 3 
(Anemia) 
Bone marrow iron  Reduced  Absent  Absent  
Serum ferritin  Reduced  <12 µg/L <12µg/L 
Transferrin saturation  Normal  <16% <16% 
Free erythrocyte 
protoporphyrin, zinc 
protoporphyrin 
Normal  Increased  Increased 
Serum transferrin 
receptor  
Normal Increased Increased 
Reticulocyte 
hemoglobin content  
Normal Decreased  Decreased  
Hemoglobin  Normal  Normal  Reduced  
Mean corpuscular 
volume   
Normal Normal  Reduced  
Symptoms  Fatigue, malaise in some 
patients  
Pallor, pica, 
epithelial changes 
 
Iron deficiency 
     A suboptimal response to recombinant human erytheropoietia  
(rhEPO) most commonly results from failure of delivery of an adequate 
amount of iron to the erythron. Enhanced iron utilization due to rhEPO-
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induced red blood cell formation can quickly deplete iron stores 
previously reduced by poor iron absorption, occult gastrointestinal 
bleeding, or dialysis-related blood losses.68 Treatment with rhEPO is, at 
this time, the most common cause of iron deficiency. Most treated 
patients become iron deficient69 and therefore require more rhEPO to 
maintain the same rate of RBC production. If the iron balance is not 
restored by oral or parenteral iron replacement and iron deficiency 
worsens, an initial good response may then falter. The most accurate 
assessment of the iron stores is given by staining the bone marrow 
aspirate for iron with Perl’s Prussian blue stain.70 
    In the lack of this reliable, but invasive, reference standard, the 
iron status is commonly assessed by serum iron concentration, serum 
ferritin (SF), transferrin saturation (TfS), and RBC indices.68 Serum iron 
concentration fluctuates during rhEPO administration, but SF, a protein 
secreted into the plasma by the reticuloendothelial cells under the 
regulation of intracellular iron concentration, is a good indicator of iron 
stores71; TfS index (calculated according to the formula: saturation % = 
serum iron/total iron capacity)–that means the transferrin-bound iron–
appears to be even better (higher sensitivity and similar specificity).70 Iron 
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deficiency secondary to the consumption of iron deposits by rhEPO-
stimulated erythropoiesis may be concealed by the persistence of 
apparently adequate ferritin levels, but it is disclosed by both a TfS level 
less than 20% and prompt erythropoietic response to intravenous 
administration of iron dextran. In a study on the early predictors of a 
response to rhEPO, the initial values of serum iron, TfS, mean corpuscular 
volume (MCV), and mean corpuscular hemoglobin concentration 
(MCHC) were significantly lower in the iron-responsive group than in the 
iron-nonresponsive one; furthermore, there was a strong inverse 
relationship between initial TfS and the change in hematocrit following 
iron therapy in patients hyporesponsive to rhEPO.72 The failure to make 
enough iron available to meet the demands of enhanced erythropoiesis 
despite the presence of adequate iron stores, as reflected by the level of 
SF, has been defined as ‘functional iron deficiency’ (compared to absolute 
iron deficiency’ or ‘iron storage deficiency’). The red blood cells appear 
hypochromic (with MCHC <28 g/dL) when mobilization of iron from 
stores and its transport to the erythron become inadequate. A percentage 
of circulating hypochromic red blood cells greater than 10% (normal 
range: <2.5% of circulating red cells), in the presence of adequate iron 
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stores and the absence of hemoglobinopathies or inflammatory diseases, 
should be diagnostic of functional iron deficiency.73,74  Other more 
sophisticated tests for iron deficiency have been proposed: erythrocyte 
ferritin75,76 ; hemoglobin content of reticulocytes (CHr); free erythrocyte 
protoporphyrin (FEP); and serum transferrin receptors (TfRC). A reduced 
erythrocyte ferritin level despite normal SF should suggest functional iron 
deficiency, a condition that measurement of both CHr and erythrocyte 
ferritin could help identify.77  
 
Chronic renal failure patients treated with hemodialysis 80,81 
 Iron deficiency affects a significant fraction of patients treated with 
hemodialysis when transfusions are restricted 84. Absolute iron deficiency 
may result from the loss of blood associated with the dialysis process and 
diagnostic tests. Gastrointestinal blood losses may also be substantial, 
averaging 6.27ml/day in one study 44. Telangiectasias are among the most 
common bleeding gastrointestinal lesions in patients with renal failure2.  
Iron kinetics in the non – dialyzed CRF patients   
 In CRF, progressive renal insufficiency leads to increasing 
anaemia. 
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 The anaemia is generally normochromic normocytic in nature due 
to hypoproliferation of bonemarrow. The iron profile values like serum 
iron, iron binding capacity, serum ferritin, percentage saturation of iron 
transferrin saturation, free erythrocyte protoporphyrin, zinc 
protoporphyrin, serum transferrin receptor and reticulocyte hemoglobin 
content are also within normal limits. However in any population where 
iron deficiency occurs due to various reasons, low iron profile or a 
microcytic hypochromic anaemia may occur7. 
  Pitfalls in iron profile studies in renal failure 82,84 
 In renal failure various pathogenic factors are in play. These 
include inflammatory and humoral factors84.  
 These factors increase the levels of various reactive proteins of 
which transferrin is also one80. This may give rise to elevated levels of 
serum iron but with decreased saturation of transferrin. Hence serum iron 
is not an accurate predictor. 
 Some authors have demonstrated low serum iron levels due to 
reactive low iron concentration and the low iron levels corresponded with 
the serum ferritin level. However the results have been inconsistent and so 
serum iron is not a reliable guide to evaluate iron status. 27,28   
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Serum Ferritin 84,77,75 
 It is frequently used to assess the iron stores for the purpose of 
ensuring their adequacy for erythropoiesis71. However measurable ferritin 
may be increased when tissue ferritin is released during cellular injury. 
Erythropoiesis blockade can increase the iron pool elevating serum 
ferritin levels despite suppressed erythropoiesis83.    
Percentage saturation of iron (SI) 
 It is a very reliable parameter that gives an indication of the iron in 
the metabolic pool. Together with serum ferritin, it is taken to assess the 
iron parameters in haemodialysis patients.     
 The National kidney foundation – disease outcome quality initiative 
has postulated that saturation <20% and ferritin <100 µg/L indicates 
decreased iron pools33. 
 
MANIFESTATIONS OF ANEMIA IN CRF 
1. The various signs and symptoms of anaemia namely tiredness, 
lethargy, fatigue, breathlessness at rest or on exertion, angina, 
palpitations, increased cold sensitivity, anorexia, loss of libido, 
menstrual irregularity, pallor, increase in heart rate, decreased 
cognition are present24.  
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2. Anemia predisposes to bleeding diathesis. This feature is poorly 
understood21. 
3. There is increased cardiac output, peripheral vasodilatation and 
increase in LV mass all of which lead to left ventricular failure in 
later stages23. 
4. Anemia leads to myocardial ischemia and angina. 
FUNCTIONAL CONSEQUENCES OF ANEMIA IN CRF 
1. Impaired cognitive capability     
 Patients on dialysis are at a disadvantage of developing dementia 
due to many causes. Iron deficiency aggravates the problem.  
2. Impaired exercise capacity  
 The exercise intolerance due to anaemia significantly increases the 
morbidity and impairs the quality of life. 
3. Cardiac death 17,18 
 The physiological response to anaemia are high stroke volume and 
an excess of catecholamines and non catecholamines due to 
chemoreceptor mediated increase in sympathetic activity. 
 Early myocardial changes are reversible if intervened effectively. 
But the late changes which include intense interstitial fibrosis and the 
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diastolic dysfunction of the heart are irreversible19,20. The vascular 
changes in CRF is arterial remodelling leading to thickening of aorta and 
stiffening. The altered systolic pressure and high inertia due to higher 
blood mass in the dilated arterial system contribute to the development of 
LVH and abnormal coronary perfusion. All these adverse changes lead to 
increase the rate of cardiac deaths in CRF. 
FACTORS AFFECTING PREVALENCE OF ANAEMIA IN CRF28 
1. Severity of renal dysfunction  
 There is a good correlation between the values of urea and 
creatinine and the quantity of hemoglobin. 
2. Type of Dialysis  
 Hemodialysis leads to more iron loss than peritoneal dialysis  
3. Trace element deficiencies  
4. Aluminium toxicity  
5. Folate and B12 deficiency      
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PRECIPITATION OF IRON DEFICIENCY ANAEMIA BY 
EPO22,30,31 
 EPO is used increasingly in the management of anaemia in CRF. 
The administration of EPO will lead to rapid depletion of the remaining 
iron stores and will precipitate iron deficiency anaemia35. 
IMPORTANCE OF DETECTING IRON DEFICIENCY ANAEMIA 
IN CRF 
 Most of the morbidity in CRF is due to anaemia to which iron 
deficiency is an important contributor. So identification and correction of 
iron deficiency anaemia improves the quality of life of CRF patients33. 
Also presence of iron deficiency leads to decrease in the effect of 
erythropoietin. Hence prompt recognition and proper correction of iron 
deficiency in CRF patients gains value30. 
  EVALUATION OF IRON DEFICIENCY ANAEMIA IN CRF 29 
 The (NKF) has formulated guidelines for the evaluation of iron 
parameters and treatment in dialysed patients, among other parameters to 
assess the adequacy of dialysis33,16.  
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GUIDELINES FOR ANEMIA OF CHRONIC KIDNEY DISEASE  
GUIDELINE 1 
An anemia work-up should be initiated in patients with chronic 
kidney disease (CKD) when the: 
• Hb <11g/dL (Hematocrit (Hct) is <33%) in pre-menopausal females and 
pre-pubertal patients  
• Hb <12g/dL (Hct is <37%) in adult males and post-menopausal females  
GUIDELINE 2 
Anemia evaluation 
A. Evaluation of anemia should consist of measurement of at least 
the following:  
•  Hemoglobin (Hb) and/or Hematocrit (Hct) 
•  Red blood cell (RBC) indices 
•  Reticulocyte count 
•  Iron parameters: 
- Serum iron  
- Total iron binding capacity (TIBC) 
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- Percent transferrin saturation (serum iron × 100 
divided by TIBC) [TSAT]  
- Serum ferritin 
• A test for occult blood in stool 
• B. This work-up should be performed before Erythropoietin therapy is 
begun.  
GUIDELINE 3 
Erythropoietin deficiency 
If no cause for anemia other than CKD is detected, based on the 
work-up outlined in Guideline 2: Anemia evaluation, and the serum 
creatinine is >2 mg/dL, anemia is most likely due to EPO deficiency.  
GUIDELINE 4: (Target Hct/ Hb for EPO therapy) 
 The target range for Hct (Hb) should be 33% (11g/dL) to 36% 
(12g/dL). This target is for EPO therapy and is not an indication for blood 
transfusion therapy.  
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III. Iron Support 
Iron is essential for hemoglobin formation, as is erythropoietin. 
Several important issues related to iron deficiency and its management in 
the CKD patient, particularly in patients receiving Erythropoetin therapy 
should be considered: 
1. Iron (blood) losses are high, particularly in the patients undergoing  
hemodialysis . 
2. Oral iron usually cannot maintain adequate iron stores, particularly 
in the hemodialysis patients treated with EPO. 
3. EPO, by stimulating erythropoiesis to greater than normal levels, 
often leads to functional iron deficiency. 
4. Prevention of functional (and absolute) iron deficiency by regular 
use of intravenous iron (ie, small doses, weekly, to replace 
predicted blood losses) improves erythropoiesis. 
5. The serum iron, total iron binding capacity, and serum ferritin are 
the best indicators of iron available for erythropoiesis and iron 
stores, but they do not provide absolute criteria for either iron 
deficiency or iron overload. 
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These guidelines suggest that the regular use of small doses of iv 
iron, particularly in the hemodialysis patient, will prevent iron deficiency 
and promote better erythropoiesis than can oral iron therapy. 
GUIDELINE 5 
Assessment of Iron status 
Iron status should be monitored by the percent transferrin saturation 
(TSAT) and the serum ferritin. 36,37,71,75,77 
GUIDELINE 6 
Target iron level 
A. CKD patients should have sufficient iron to achieve and 
maintain an Hgb/Hct of 11 to 12 g/dL/33% to 36%.  
B. To achieve and maintain this target Hgb/Hct, sufficient iron 
should be administered to maintain a TSAT of >20%, and a serum ferritin 
level of >100 ng/mL . 
C. In hemodialysis patients in whom TSAT is >20% and the serum 
ferritin is >100 ng/mL, yet the Hgb/Hct is 11 g/dL/<33%, as well as in 
patients requiring comparatively large doses of erythropoietin to maintain 
an Hb/Hct of 11 to 12 g/dL/33% to 36%, the patient’s response to 1.0 g of 
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iv iron given over 8 to 10 weeks should be observed. If in response to this 
course of iron, there is no increase in Hb/Hct and no increase in serum 
ferritin and TSAT level, at the same dose of EPO a second course of iv 
iron should be tried. If, in response to this second course of iv iron, there 
still is no increase in Hb/Hct, but either the TSAT or serum ferritin level 
increases, then the weekly dose of iv iron should be reduced to the lowest 
amount required to maintain the TSAT >20% and serum ferritin at >100 
ng/mL. If, on the other hand, in response to either of these courses of iv 
iron, there is an increase in Hb/Hct at a constant dose of EPO, or a stable 
Hct at a decreased dose of EPO, then it is reasonable to administer 1.0 g 
of iron iv over 8 to 10 weeks again in an effort to achieve and maintain 
the Hb/Hct at 11 to 12 g/dL/33% to 36%.  
D. CKD patients are unlikely to respond with a further increase in 
Hb/Hct and/or a further reduction in EPO dose required to maintain a 
given Hb/Hct if the TSAT increases to >50% and/or the serum ferritin 
level increases to >800 ng/mL.  
     Fernandez – Roudriguez et al have studied 63 patients with chronic 
renal failure undergoing dialysis and have concluded that serum ferritin 
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may be the most reliable parameter and saturation index is not a reliable 
parameter for diagnosing iron deficiency34. 
 Milman W, Bangawell S et al who studied 50 non dialysis patients 
and 53 controls, have also predicted serum ferritin as a useful indicator of 
marrow iron stores in patients, with renal failure38.  
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STUDY DESIGN 
  
 This study was conducted at Government Rajaji Hospital between 
period of June 2006 to March 2007.A total of 43 patients who were 
diagnosed to have Chronic kidney disease who were undergoing 
conservative management were enrolled into the study. Serum ferritin 
assay in subjects and  controls using  ELISA method were done  at the 
Department of Biochemistry, Madurai Medical College. The study was 
approved by the Ethical committee, Government Rajaji Hospital.  An 
informed consent was obtained from all study participants. 
Nature of Study: Analytical Study,  
Sample Size  - 43 
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MATERIALS AND METHODS 
Materials: 
 43 patients from medicine wards and nephrology ward  
Diagnostic criteria: 
1. Bilateral contracted kidneys 
2. GFR <60 mL/min/1.73m2. 
    Exclusion criteria:  
 Conditions that may alter the iron profile and RBC morphology 
were excluded on the basis of detailed history and clinical examination 
and basic investigations   
They include: 
1. All female patients  
2. Chronic infections like tuberculosis, rheumatoid arthritis  
3. Malignancies 
4. Hemoglobinopathies 
5. Bleeding disorders 
6. Nephrotic syndrome 
7. Chronic liver disease 
8. HIV infection 
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9. Malabsorption 
10. Steroid therapy 
11. Patients receiving EPO therapy  
Methods: A proper medical history from the patients were obtained 
which included the past history of diabetes mellitus, family history of 
renal disease, hypertension, coronary artery disease, drug history 
including nephrotoxic drugs, intercurrent illness and dietary habits  
Clinical examination included: 
1. Weight ,height body mass index (BMI) ,mid arm circumference 
(MAC) 
2. Vital parameters 
3. Major systems examination  
Hematological investigations: 
Hemoglobin , peripheral smear TC DC platelet count  
Biochemical investigations: 
Blood sugar 
Renal parameters (blood urea serum creatinine) 
 43
Total proteins and serum albumin 
Urine spot protein creatinine ratio 
Serum ferritin : The serum ferritin was determined by using UBI – 
MAGIWEL ferritin kit ( United biotech Inc California USA) by enzyme 
linked immunosorbent assay (ELISA using Robanik easy ELISA reader )  
 
Ethical committee approval  : Obtained  
Consent     : Informed consent was obtained  
Financial support     : Nil  
Conflict of interest    : Nil  
The information collected regarding all the selected cases were 
recorded in a master chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2002). 
  
Using this software, frequencies, percentage, mean, standard 
deviation, x2 and 'p' values were calculated. A 'p' value less than 0.05 is 
taken to denote significant relationship. 
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RESULTS 
A. Characteristics of cases included in the study 
Table 1 
Distribution of patients in relation to age   
Study cases Age group 
No. % 
Below 30 4 9.3 
30-39 3 7 
40-49 10 23.3 
50-59 18 41.9 
60 & above 8 18.6 
Total 43 100 
Mean 
S.D. 
49.8 yrs 
12.1 yrs 
 
Among the 43 male patients enrolled in the study the mean age was 
49.8. The patients between the 3rd and 7th decade form the major number 
of the study.   
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Table 2 
Risk Factors 
 
Present Absent Risk factor 
No. % No. % 
Diabetes 3 7 40 93 
Hypertension 12 27.9 31 12.1 
Smoking 15 34.9 28 65.1 
B.P. 30 69.8 13 30.2 
LVH 12 27.9 31 72.1 
 
Assessing the risk factors of CKD in our patients it was found that 
diabetes mellitus contributed to only a meagre 7% of our patients. 
Significant history of hypertension was present in about 28% of our study 
group which may be either the cause or effect of CKD . Prevalence of 
smoking was present in about 35% of our patients. 70% of our study 
group were hypertensives at the time of diagnosis and out of them 28 % 
had LVH by ECG criteria, which is a significant risk factor for coronary 
artery disease. In our population apart from diabetes and hypertension 
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other causes of CKD are predominant especially in the young like primary 
glomerulonephritis, interstitial nephritis and so on. 
Table 3 
Mean values of baseline parameters 
Parameter Mean S.D. 
Weight 50.8 kg 8.1 kg 
Height 161 cm 7 cm 
BMI 19.56 2.78 
MAC 21.6 1.8 
Hb 7.04 1.93 
PCV 21.8 6 
Urea 156 61.6 
Serum creatinine 7.35 4.19 
Total protein 6.48 0.81 
Albumin 3.28 0.41 
GFR 11.5 6.21 
Ferritin 86.9 70.9 
 
In our study group the mean body mass index (BMI) of the patients 
was 19.56, which was low normal. Mid arm circumference also was less 
 47
for the age. (mean 21.6 cm). All the patients in our study were anemic 
with a mean Hb of 7.04 g/dl. Hypoalbuminemia was highly prevalent in 
our patients (mean – 3.28g/dl). The mean GFR of our patients were 11.5 
ml/mt. Most of our patients came under the stage 4 and 5 of CKD staging 
and has either dialysis or transplant as their treatment option. Serum 
ferritin was also far below the recommended value in patients with CKD 
by NKF guidelines (>100 mcg/l).  
  Table 4 
C.K.D Stage and cases 
 
Study Cases C.K.D. Stage 
(ml/mt/1.73mt2) No. % 
Stage I (GFR > 90) - - 
Stage II (GFR 60-89) - - 
Stage III (GFR 30-59) - - 
Stage IV (GFR 15-29) 12 27.9 
Stage V (GFR < 15) 31 72.1 
Total 43 100 
 
Most of our patients were ESRD patients 
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Table 5 
Type of peripheral smear (PS) 
Study Cases PS Type 
No. % 
Microcytic Hypochromic (MC) 13 30.2 
Dimorphic anaemia (DA) 17 39.6 
Normocytic normochromic (NA) 13 30.2 
Total 43 100 
 
Microcytic hypochromic anemia was present in about 30% of our 
group. Normocytic normochromic anemia was seen in about 30% of the 
population. The remainder had dimorphic anemia. 
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B. Relationships between parameters and GFR and ferritin 
Table 6 
Age and GFR and serum ferritin 
 
GFR Serum Ferritin Age Group 
Mean S.D. Mean S.D. 
Below 30 5.29 0.57 30.75 18.14 
30-39 5.97 1.6 125.33 78.27 
40-49 11.37 6.12 76.3 83.03 
50-59 13.98 6 77.61 69.14 
60 & above 11.27 6.61 84.63 66.84 
‘p’ 0.0198 
(Significant) 
0.3137 
(Not significant) 
 
 Age and GFR have statistically significant relationship. No such 
relationship exists between age and ferritin. 
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Table 7 
Relationship between BMI and GFR and serum ferritin 
 
GFR Serum Ferritin BMI 
Mean S.D. Mean S.D. 
Underweight (<18.5) 10.6 6.39 87.69 71.02 
Normal (18.5 –24.9) 12.42 6.22 75.56 70.79 
Overweight (25-30) 7.15 2.46 22 2.83 
Obese (> 30) - - - - 
‘p’ 0.4093 (Not significant) 0.2151 (Not significant) 
 
 BMI has got no statistically significant relationship with GFR and 
ferritin. 
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Table 8 
Relationship between C.K.D Stage (GFR) and Mid arm 
circumference (MAC) 
 
MAC C.K.D. Stage 
(ml/mt/1.73mt2) Mean S.D. 
Stage I (GFR > 90) - - 
Stage II (GFR 60-89) - - 
Stage III (GFR 30-59) - - 
Stage IV (GFR 15-29) 22.26 1.67 
Stage V (GFR < 15) 21.35 1.81 
‘p’ 0.2376 (Not significant) 
 
CKD stage does not affect MAC values significantly. 
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Table 9 
 
Relationship between C.K.D Stage (GFR) and Anemia (Hb)  
 
Hb C.K.D. Stage 
(ml/mt/1.73mt2) Mean S.D. 
Stage I (GFR > 90) - - 
Stage II (GFR 60-89) - - 
Stage III (GFR 30-59) - - 
Stage IV (GFR 15-29) 8.96 1.76 
Stage V (GFR < 15) 6.3 1.43 
‘p’ 0.0001 (Significant) 
 
 As CKD stage increases Hb levels decrease. This relationship is 
statistically significant. 
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Table 10 
Relationship between CKD stage and PCV, urea and Sr. creatinine 
 
PCV Urea Sr Creatinine CKD Stage 
(ml/mt/1.73mt2) No. % No. % No. % 
Stage I (GFR > 90) - - - - - - 
Stage II (GFR 60-89) - - - - - - 
Stage III (GFR 30-59) - - - - - - 
Stage IV (GFR 15-29) 27.38 5.09 104.36 40.49 3.09 0.57 
Stage V (GFR < 15) 19.65 4.88 176 56.78 9 3.79 
‘p’ 0.0002 
(Significant) 
0.0004  
(Significant) 
0.0001 
(Significant) 
 
 
 As CKD stage increases, packed cell volume (PCV) levels decrease 
and urea and serum creatinine values increase. These relationships have 
got statistical significance. 
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Table 11 
Relationship between CKD stage and Total protein and Albumin 
 
Total Protein Albumin CKD Stage 
(ml/mt/1.73mt2) Mean S.D. Mean S.D. 
Stage I (GFR > 90) - - - - 
Stage II (GFR 60-89) - - - - 
Stage III (GFR 30-59) - - - - 
Stage IV (GFR 15-29) 6.34 0.88 3.28 0.57 
Stage V (GFR < 15) 6.53 0.78 3.29 0.33 
‘p’ 0.5238  
(Not Significant) 
0.9132  
(Not Significant) 
 
 There is no statistically significant relationship between CKD Stage 
and the values of total protein and albumin. 
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Table 12 
Relationship between Left ventricular hypertrophy (LVH) and GFR 
and Sr. Ferritin 
GFR Sr. Ferritin LVH 
 Mean S.D. Mean S.D. 
Present (12) 9.73 5.19 49.75 36.3 
Absent (31) 12.19 6.51 88.35 76.69 
‘p’ 0.2554  
(Not significant) 
0.1551  
(Not significant) 
 
 GFR and Ferritin values are not significantly affected by the 
presence or absence of LVH. 
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Table 13 
 
PS and GFR and Sr. Ferritin 
 
GFR Sr. Ferritin PS 
Mean S.D. Mean S.D. 
Microcytic hypochromic (MC - 13) 9.94 5.27 23.15 8.58 
Dimorphic (DA - 17) 11.03 6.55 88.53 78.02 
Normocytic Normochromic (NA - 13) 13.68 6.47 117.69 60.62 
‘p’ 0.2369  
(Not significant) 
0.0001  
(Significant) 
 
 
 There is statistically significant relationship between ferritin values 
and type of PS. No such relationship exists in the case of GFR values and 
PS type. Serum ferritin values were very low in patients with microcytic 
hypochromic anemia  
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Table 14 
Comparison of serum ferritin values in cases and controls 
Serum Ferritin Group 
Mean S.D. 
Study cases 77.58 69.67 
Controls 108.11 70.98 
‘p’ 0.029   
(Significant) 
 
 The mean ferritin values of the study cases are significantly lower 
than that of the controls. 
Table 15 
Relationship between stage of CKD and serum ferritin 
Serum Ferritin CKD Stage 
(ml/mt/1.73mt2) Mean S.D. 
IV (GFR 15-29) 97.7 89.8 
V (GFR< 15) 69.8 60.1 
‘p’ 0.507 (not Significant) 
 
No statistically significant relationship was observed between GFR 
and serum ferritin values. 
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Table 16 
Comparison of total protein values in study and control groups 
Total protein Group 
Mean S.D. 
Study 6.48 0.8 
Control 6.12 0.5 
‘p’ 0.1344 
(not Significant) 
 
Serum total proteins were not significantly lesser in patients with 
CKD 
 
Table 17 
Serum albumin values in study and control groups 
 
Serum albumin Group 
Mean S.D. 
Study 3.28 0.41 
Control 4.33 0.25 
‘p’ 0.0001 
(Significant) 
 
Serum albumin showed a marked reduction in patients with CKD 
when compared to the normal controls 
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Table – 18 
 
Distribution of BMI values in cases  
 
Cases BMI 
(kg/m2) No. % 
Underweight (<18.5) 16 37.2 
Normal (18.5 –24.9) 25 58.1 
Overweight (25-30) 2 4.7 
Obese (> 30) - - 
Total 43 100 
 
 
About 37% of the total CKD patients were underweight (BMI<18.5) 
 
 
 
 
 
 
 
 
 60
Table – 19 
 
Relationship between BMI  and Serum Albumin 
 
Serum Albumin BMI 
(kg/m2) Mean S.D. 
Underweight (<18.5) 3.34 0.33 
Normal (18.5 –24.9) 3.26 0.46 
Overweight (25-30) 3.3 0.42 
Obese (> 30) - - 
Total 3.28 0.41 
‘p’ 0.6819 
(Not significant) 
 
 
There was no statistically significant relationship between 
nutritional parameters of BMI and serum albumin. 
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Table 20 
Relationship between C.K.D Stage (GFR) and BMI 
BMI C.K.D. Stage 
(ml/mt/1.73mt2) Mean S.D. 
Stage I (GFR > 90) - - 
Stage II (GFR 60-89) - - 
Stage III (GFR 30-59) - - 
Stage IV (GFR 15-29) 19.84 1.94 
Stage V (GFR < 15) 19.45 3.06 
‘p’ 0.4323 (Not significant) 
 
No significant relationship was seen between GFR and BMI 
 
Table 21 
Comparison BMI values in cases and controls 
BMI Group 
Mean S.D. 
Study cases 19.56 2.78 
Controls 23.4 2 
‘p’ value  0.0001  (Significant) 
 
 The mean BMI of the study cases are significantly lower than that 
of the normal controls. 
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DISCUSSION 
The dawn of 21st century has witnessed the emergence of chronic 
kidney disease as a global pandemic due to increasing incidence of 
predisposing factors like hypertension diabetes etc with an incidence of 
6% in adult population 
In patients with chronic kidney disease anemia and protein 
malnutrition are the two important predictors of mortality and morbidity 
Numerous studies have demonstrated disorders of protein 
metabolism in uremia. Many of the abnormalities in protein metabolism 
associated with chronic renal failure persist in patients undergoing 
hemodialysis. The quantities of various essential and nonessential amino 
acids and their various ratios are altered in plasma,56,57  muscle,58 and red 
blood cells.59  In addition, the turnover of albumin is altered, which, along 
with many other factors, contributes to a decrease in the serum albumin 
concentration in dialysis Patients.57,60 
Serum albumin levels have been used extensively to assess the 
nutritional status of individuals with and without chronic renal failure 
(CRF). 85,86,76 Malnutrition is common in the end-stage renal disease 
(ESRD) population, and hypoalbuminemia is highly predictive of future 
 63
mortality risk when present at the time of initiation of chronic dialysis as 
well as during the course of maintenance dialysis (MD).85-88 It follows that 
nutritional interventions that maintain or increase serum albumin 
concentrations may be associated with improved long-term survival, 
although this has not been proven in randomized, prospective clinical 
trials. Serum albumin levels may fall modestly with a sustained decrease 
in dietary protein and energy intake and may rise with increased protein or 
energy intake. Conversely, serum albumin levels may fall acutely with 
inflammation or acute or chronic stress and increase following resolution 
or recovery44,45. 
Although no single ideal measure of nutritional status exists, the 
serum albumin concentration is considered to be a useful indicator of 
protein-energy nutritional status in MD patients 91,94,95. The extensive 
literature, in individuals with or without renal failure, relating serum 
albumin to nutritional status, and the powerful association between 
hypoalbuminemia and mortality risk in the MD population, strongly 
support this contention. In addition, the measurement of serum albumin 
levels is inexpensive, easy to perform, and widely available. 
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The progressive reduction in voluntary protein intake observed as 
patients approach end-stage renal failure, considered in light of the 
increasing prevalence of hypoalbuminemia with its attendant ominous 
implications for dialysis patients,55 has led to the suggestion that 
increasing protein intake can prevent complications.52,90,92 However, the 
inference that encouraging a high-protein diet will counteract 
hypoproteinemia is not borne out by experimental evidence90. on the 
contrary, a protein-restricted diet, including those supplemented by 
essential amino acids, improves protein nutrition while 
ameliorating uremic symptoms, whereas a more "nearly normal" diet has 
the opposite effects. Thus, hypoalbuminemia  can be prevented by 
prescribing a well- designed, low-protein diet. The suggestion that such 
diets will induce protein malnutrition has been repeatedly disproven. The 
largest study of this question, the Modification of diet in renal disease 
(MDRD) study, established unequivocally that low-protein diets as well 
as supplemented very-low-protein diets are nutritionally safe 89 
Anemia of chronic kidney disease is multifactorial in orgin 
whatever be the cause it  is directly associated with increased mortality 
from cardiac diseases 
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The renal community has long recognized that anaemia can impair the 
quality of life of patients and lead to irreversible cardiac consequences. 
Anaemia, which occurs frequently and is often neglected, appears to 
precede left ventricular hypertrophy and CHF in renal transplant patients. 
Anaemia may not be an 'innocent bystander' in chronic disease;Anemia, 
an easily reversible feature of end-stage renal disease, is an independent 
risk factor for clinical and echocardiographic cardiac disease, like left 
ventricular dilatation as well as mortality in end-stage renal disease 
patients 17-20. 
Available evidence demonstrates that: 
Both iron and erythropoietin are needed to produce red blood cells; 
as a result, unless adequate iron is available, Erythropoietin will be 
relatively ineffective 28,30. 
Although no tests are perfect indicators of the adequacy of iron 
stores, the TSAT and serum ferritin are the best measures of the body’s 
iron status that we currently have. The probability that iron deficiency 
is present increases as the values of these measures decrease 34-36,41,42. 
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Given the prevalence of iron deficiency in CKD patients, and the 
sensitivity and specificity of TSAT and serum ferritin in detection of iron 
deficiency, the likelihood of iron deficiency is sufficiently high when 
TSAT is <20% and the serum ferritin is <100 ng/mL. Therefore, the 
TSAT and serum ferritin should be maintained at a level of >20% and 
>100 ng/mL, respectively, in all patients 33. 
This study was undertaken with the aim of identifying the 
prevalence of iron deficient anemia in patients with chronic kidney 
disease and also the prevalence of protein energy malnutrition  
Among the 43 male patients selected for the study the mean age of 
the study group was 49.8yrs  In assessing the risk factors of chronic 
kidney disease in our patients the incidence of diabetes was only found to 
be 7% meanwhile 27.9% of the population had history of hypertension. 
This points to the fact that in our part of the world diabetes is not the 
prime cause of CKD. The various other causes like glomerulonephritis 
interstitial nephritis, analgesic nephropathy etc may be the leading cause 
of CKD and ESRD.   
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About 35% of the population of the patients were  chronic smokers, 
which is also an important risk factor for progressive decline in GFR and 
ESRD. 
At the time of presentation about 70% of the patients were 
hypertensives and among them about 28% had left ventricular 
hypertrophy by ECG criteria. These two form the major risk factors for 
cardiovascular death in patients with CKD  
Anthropometric measurements were taken in patients, which 
included weight, height, body mass index, and mid arm circumference.  
It is found that the BMI was significantly lower in our patients with 
a mean of 19.56%, which was lower when compared to the control 
population .37.2% of the patients were underweight (<18.5) according to 
The National Institute Of Health guidelines. This indicates that a 
significant proportion of our patients are malnourished. 
In our study we compared the BMI of the CKD patients to that of 
the controls. The mean BMI of the study group was 19.56 and that of 
controls were 23.4. The BMI was significantly lower in the study group 
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once again reinforcing the fact that protein calorie malnourishment is very 
common in CKD patients. 
Also the mid arm circumference was also significantly lower in our 
patients (mean of 21.6 cm) It is a crude indicator of somatic protein 
stores. 
The mean hemoglobin in our patients was 7.04 g/dl and the mean 
GFR was 11.5 ml/mt. Anemia was universal in our study and it showed 
direct linear relationship with reductions in the GFR. Applying the NKF 
staging of CKD most of our patients came under stage 4 and 5 who were 
awaiting some form of renal replacement therapy as the last treatment 
option  
Peripheral smear was done in our patients with the aim to type the 
anemia .As the conventionally taught normocytic normochromic anemia 
was found in 30.2 % of the patients and microcytic hypochromic anemia 
in another 30%, the remainder had dimorphic anemia. This clearly 
indicates that iron deficiency anemia is a major component in the anemia 
of chronic kidney disease due to various reasons discussed earlier.  
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Significant hypoalbuminemia was present in our study with the 
mean serum albumin level of 3.28g/dl that was significantly lower than 
the normal controls (p value 0.0001). There was no statistically significant 
relationship between the GFR and serum albumin and also BMI and 
serum albumin.  
Serum ferritin value was measured in our patients and healthy 
controls and found to be significantly less in our patients (p value 0.029). 
There existed no relationship between GFR and serum ferritin. As 
expected those patients with microcytic hypochromic anemia had a 
relatively lower serum ferritin when compared to the other types 
  By applying the NKF guidelines 30 patients out of the total 43 had 
a serum ferritin below 100ng/ml, which comes to around 69.76% of the 
patients.  
In a similar study by IA Agaba et al have assessed the prevalence of 
malnutrition in patients with CRF in Nigeria 40. In this study the BMI was 
significantly lower than the controls with a mean of 22.4 kg/m2 and low 
BMI of less than 20 kg/m2 was present in about 21.6% of the patients. In 
our present study the mean BMI was only 19.56% and proportion of those 
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who are underweight (< 18.5 kg/m2) were 16 (37.2 %) among the total 43 
patients.   
The mean serum total protein and albumin were also significantly 
lower in the patients compared to controls (61.9 +/- 14.4 g/L Vs. 73.8 +/- 
6.8 g/L; p < 0.0001, and 31.5 +/- 9.3 g/L Vs. 39.6 +/- 4.4 g/L; p < 0.0001 
respectively) in the Nigerian study 
In comparison, our study showed the mean serum albumin was 
significantly lower when compared to the controls (3.28 +/- 0.41g/dl Vs 
4.33+/- 0.25 g/dl; p value 0.0001) 
Protein malnutrition (serum albumin < 3.0 g/L) was present in 32 
(43.2%) patients with CRF in the Nigerian study and the corresponding 
value in our study was 13 out of 43 patients (30.2%) 
The results of both the studies were very much similar and 
emphasis should be placed on prevention and/or correction of 
malnutrition because of its documented adverse effects on the outcomes 
of maintenance dialysis. 
 71
In a study conducted by Mafra D et al with the aim to assess the 
zinc and iron status in patients with chronic renal failure (CRF) who were 
not receiving dialysis the serum ferritin and other parameters were 
assessed among 29 CRF patients. The serum ferritin level was reduced to 
a mean of 85.5 +/- 67.1 ng/mL. In our study the corresponding values 
were 77.58 +/- 69.67 among the 43 patients. The results of the two studies 
were similar. 
 So every effort should be done to identify and treat the 
coexistent iron deficiency anemia in patients with chronic kidney disease. 
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LIMITATIONS OF THE STUDY: 
As the study population was small larger studies are required to 
validate  the results of this study.   
The protein energy malnutrition in CKD patients should be 
evaluated using multiple parameters including the SGA( subjective global 
assessment) ,other serum markers including serum transferrin , pre 
albumin, IGF-1 etc apart from albumin which was evaluated in our study.  
Iron deficiency in CKD should be assessed by using other 
parameters like transferrin saturation, serum TIBC, newer methods which 
include soluble transferrin receptors, zinc protoporphyrin and the gold 
standard method, the bone marrow examination for stainable iron. Here 
serum ferritin and peripheral smear were the only parameters studied. 
Also in our patients the probable causes of iron deficiency like 
occult GI bleed were not excluded by stool for occult blood or upper GI 
endoscopy.  
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SUMMARY 
This study was undertaken with the aim to assess the nutritional 
status in patients with chronic kidney disease who were not on regular 
dialysis.  
A total of 43 patients were included in our study who satisfied the 
diagnostic criteria of CKD and were evaluated for various parameters like 
weight, height, BMI, midarm circumference, serum total proteins 
hemoglobin, peripheral smear and serum ferritin to find out malnutrition 
and iron status. 
For comparison of the results with the general population adequate 
number of controls were also taken.  
A significant proportion of our patients were having protein energy 
malnutrition as evidenced by the low BMI and very low serum albumin 
when compared to the normal controls. 
Anemia was universal in our population and iron deficiency anemia 
was a major cause for this in our study as shown by peripheral smear and 
very low serum ferritin.       
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CONCLUSION 
Protein energy malnutrition was widely prevalent in our population 
of end stage CKD patients as evidenced by very low serum albumin and 
BMI. 
Profound anemia was universal in our patients, which is an 
important contributor to the high mortality and morbidity in patients with 
ESRD 
Among the anemic patients, iron deficiency anemia formed a major 
proportion which has to be corrected by giving iron therapy either oral or 
by parenteral route before starting on erythropoetin or dialysis therapy. 
Applying the NKF guidelines to our population it was found that nearly 
70% of the study population didnot have target serum ferritin of 100 
ng/ml so it is vital to address this issue of iron deficiency in patients with 
chronic kidney disease so that necessary investigations can be undertaken 
to find the cause of iron deficiency if any. 
Also adequate supplementation of iron should be given either as oral or 
parenteral route before initiation of dialysis or erythropoetin therapy to 
attain the goal according NKF guidelines.  
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Hypoalbuminemia was also present in a significant proportion of our 
patients, which is an important predictor of morbidity especially in 
patients on hemodialysis.  In the light of MDRD study it has been shown 
that a well-designed low protein diet can prevent hypoalbuminemia and 
its attendant complications.  
 Eventhough treating the complication of CKD like anemia , PEM 
etc will reduce the mortality and improve the survival , our ultimate aim 
should be focused on the preventive strategies for CKD . This include 
screening high risk population , control of hypertension , DM, limiting the 
use of nephrotoxic drugs like NSAID’S so that a large section of our 
population escape the burden of this killer disease       
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PROFORMA  
 
 
NUTRITIONAL ASSESSMENT IN PATIENTS WITH CHRONIC 
KIDNEY DISEASE 
 
 
Name:      Age:   Gender: 
Ip no/address:        Occupation: 
       
  
Chief complaints: 
 
Past history: 
Duration of illness: 
Renal disease:       HT: DM:  Nephrotic syndrome:
     
Personal history: 
Smoking:        Alcohol: 
Veg/ non-veg: 
 
Family history: 
 
General Examination: 
 
   Pedal edema:       Anemia:    
 
 
Vital data:  
PR:    BP:    RR: 
Weight:   BSA:    Height: 
BMI: 
 
GFR: 
 
Mid arm circumference: 
INVESTIGATIONS: 
 
 
Complete Hemogram: 
 
Hemoglobin: 
PCV:  TC:  DC:  BT:    CT: 
 
Peripheral Smear: 
 
 
Biochemistry: 
Blood sugar: 
Blood urea:     Serum Creatinine: 
Total protein: 
Albumin: 
 
 
Serum ferritin: 
 
 
      
Urine examination:  
Microscopy: 
Albumin:       Sugar: 
Deposits: 
 
USG abdomen: 
 
 
 
 
 
KEY NOTES MASTER CHART 
 
 
DM  - Diabetes mellitus  
HT  - Hypertension 
BP  - Blood pressure  
WT  - Weight (kg)  
Ht  - Height (cm)  
BMI  - Body mass index  
MAC  - Mid arm circumference (cm)  
Hb  - Hemoglobin (g/dl)  
PCV   - Packed cell volume  (%)  
S Cr  - Serum creatinine ( mg/dl)  
B. urea - Blood urea ( mg/dl)  
T pro   - Total protein ( g/dl)  
S. alb   - Serum albumin ( g/dl)  
LVH  - Left ventricular hypertrophy  
GFR  - Glomerular filtration right ( ml/mt/1.73m2) 
SF  - Serum ferritin ( mcg/dl) 
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